Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  anti-thymocyte globulin
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 81 for your search:
Start Over
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 40 to 60
Sponsor: Other
Protocol IDs: 2013-08, NCT01856803
ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2013(56), NCT02290132
Unrelated Double Umbilical Cord Blood Units Transplantation
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 50
Sponsor: Other
Protocol IDs: HORCSCT-0902, NCT01015742
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
Phase: Phase III
Type: Supportive care
Status: Active
Age: 19 and under
Sponsor: Other
Protocol IDs: ProfGVHD1, NCT00934557
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation
Phase: Phase III
Type: Supportive care
Status: Active
Age: 16 to 70
Sponsor: Other
Protocol IDs: CBMTG 0801, NCT01217723
Comparison of Cy-Atg Versus Flu-Atg for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) for Bone Marrow Failure Syndrome
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: C-021, NCT01145976
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CBMTC-AML-1, NCT01751997
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 to 70
Sponsor: Other
Protocol IDs: 2067.00, NCI-2011-01352, R01AI041721, FHCRC-2067.00, 6364, NCT00622895
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 60
Sponsor: Other
Protocol IDs: MT2000-09, 0001M34441, UMN-MT2000-09, UMN-2007BMT031, NCT00630253
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: CCI #07-00119, CHLA-#07-00119, NCT00730314
Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536
HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: AMCPHO-SCT0902, NCT01509300
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0249, NCI-2012-01248, NCT01629511
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0265, NCI-2012-02072, NCT01664910
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2012-0506, NCI-2012-02055, NCT01701986
Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: 2012-0819, RP110553-P3), NCI-2013-00993, NCT01823198
Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: NHLBI
Protocol IDs: CDR0000066610, NHLBI-97-H-0196, NCT00003553
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
MiniMUD Study - Unrelated Reduced Intensity Conditioning With Treosulfan® for Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 2003.332, NCT00129155
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
Early Allogeneic Blood Stem Cell Transplantation in High-Risk Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: DDEATX, NCT00188136
Start Over